Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

873.68 +0.56 (+0.06%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Eli Lilly’s $123 Billion Market Value Drop: A Strategic Buying Opportunity?
JPMorgan analyst says Eli Lilly will remain a leader in weight loss drugs. 
Via Talk Markets
3 Overlooked Stocks Poised for a Breakout Very Soon
Discover three overlooked breakout stocks with solid growth prospects, perfect for enhancing your investment portfolio. 
Via InvestorPlace
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
There's reason to believe that one of these two players will eventually win. 
Via The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Roche's latest breakthrough could be a game changer, but it's still too early to say. 
Via The Motley Fool
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Should you get in on this stock now? 
Via The Motley Fool
Is Eli Lilly Stock a Buy?
The stock is up 250% in three years on growth in GLP-1 medications. 
Via The Motley Fool
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
7 Smart Stocks to Buy BEFORE They Report Q2 Earnings
If you want to make the right moves in the next couple of weeks, consider buying the best stocks to buy before earnings reports are final. 
Via InvestorPlace
Home Depot Stock Turned $1,000 Into $17.5 Million, and One of Its Founders Just Revealed His Investing Secrets to Achieve Generational Wealth
Home Depot founder Ken Langone recently shared his investment wisdom on the American Optimist podcast. 
Via The Motley Fool
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
The company should maintain its lead in this growing area. 
Via The Motley Fool
These 2 Growth Stocks Are Set to Soar This Summer and Beyond
It's a great time to invest in wonderful stocks. 
Via The Motley Fool
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
These companies are no strangers to beating the market. 
Via The Motley Fool
SPDR ETF Report For Friday, July 26
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, July 26. 
Via Talk Markets
Topics ETFs
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Small caps continued to lead, while the Nasdaq broke below key levels. 
Via Investor's Business Daily
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards... 
Via Benzinga
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
Biogen partner Eisai is planning to ask European regulators to re-examine their decision. 
Via Investor's Business Daily
Prediction: This Is What Eli Lilly Stock Will Do Next
Shares of Eli Lilly are up more than 130% in the past year, but this company's moves are far from finished. 
Via The Motley Fool
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Thursday, major U.S. indices showed mixed results. The Dow Jones Industrial Average increased by 0.2% to 39,935.07. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category. 
Via The Motley Fool
7 Explosive Growth Stocks Set to Soar in 2024
These seven explosive growth stocks across various sectors have the potential to deliver substantial returns for investors in 2024. 
Via InvestorPlace
Novo Nordisk Shares Decline Amid Competitive Pressure
Novo Nordisk A/S Common Stock (NYSE: NVO) experienced a notable decline on Thursday. This movement follows a significant announcement from competitor Viking Therapeutics Inc. (NASDAQ:VKTX). 
Via Benzinga
3 Top-Performing Stocks Beating the Big Names in 2024
The following top-performing stocks may continue to gain as the Magnificent Seven runs out of steam in July. 
Via InvestorPlace
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
Viking Therapeutics Inc (NASDAQ:VKTX) shares are rising Thursday after the biotech company announced plans to advance its experimental weight loss drug to late-stage trials. 
Via Benzinga
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Eli Lilly and Company stock is trading lower on Thursday after Viking Therapeutics announced the advancement of its novel treatment for obesity, VK2735. 
Via Benzinga
3 Companies Gearing Up for a Stock Split
These stock split candidates could follow the route of Nvidia, Walmart and Chipotle Mexican Green in the near future. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Via Benzinga
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug. 
Via Investor's Business Daily
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback